Document is current
Any future updates will be listed below
-
Authors
Arrizabalaga, Leire
Di Trani, Claudia Augusta
Fernández-Sendin, Myriam
Bella, Ángela
Russo-Cabrera, Joan Salvador
Gomar, Celia
Ardaiz, Nuria
Belsue, Virginia
González-Gomariz, José
Zalba, Sara
Gil-Korilis, Adrián
Garrido, Maria J.
Melero, Ignacio
Aranda, Fernando
Berraondo, Pedro
-
Funding
Funding for this research was provided by:
FPU grant from The Spanish Ministry of Education and Professional training (FPU21/00042)
ISCIII (Instituto de Salud Carlos III), cofinanced by FSE (CP19/00114)
Instituto de Salud Carlos III and co-financed by the European Union (PI20/00203 and PI22/00147)
Gobierno de Navarra Proyecto ARNMUNE (0011–1411-2023)
Leonardo Grant for Researchers and Cultural Creators (2022)
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 2 February 2025
First Online: 17 February 2025
Declarations
:
: All the experiments received approval (R-080–19GN) from the Ethics Committee for Animal Testing at the University of Navarra.
: Not applicable.
: Ignacio Melero reports receiving commercial research grants from AstraZeneca, BMS, Highlight Therapeutics, Alligator, Pfizer Genmab and Roche; has received speakers bureau honoraria from MSD; and is a consultant or advisory board member for BMS, Roche, AstraZeneca, Genmab, Pharmamar, F-Star, Bioncotech, Bayer, Numab, Pieris, Gossamer, Alligator and Merck Seron.The rest of the authors report no conflicts of interest in this work.
